An interview session with CEO and Co-founder of CMTx Biotech. 

Mr. Scaduto is currently the Co-Founder and CEO of CMTx Biotech, a clinical-stage biopharmaceutical company working to commercialize a pipeline of proprietary, non-antibiotic, chemically-modified tetracycline (CMT) compositions and formulations for the host-modulatory treatment of diseases with high unmet needs. The company’s lead drug candidate is a clinical-stage, orally-administered small molecule (incyclinide / CMT-3 / COL-3) for the treatment of hospitalized sepsis patients at risk of septic shock, multiple organ dysfunction syndrome (MODS) and acute respiratory distress syndrome (ARDS), including from SARS-CoV-2 infection (COVID-19) and other infectious diseases. Mr. Scaduto is also the Founder and CEO of Traverse Biosciences Inc., an emerging bioscience company commercializing a proprietary library of novel drug candidates to treat chronic inflammatory conditions affecting humans and animals. Mr. Scaduto is also a Co-Founder and Managing Partner of Hairpin Technologies Inc., the exclusive licensing agent of Cold Spring Harbor Laboratory (CSHL) to expand the commercial distribution and use of small hairpin RNA (shRNA). Mr. Scaduto was previously designated as an external BioEntrepreneur-In-Residence (B-EIR) at the Center for Biotechnology, a New York State Center for Advanced Technology (CAT) at Stony Brook University

Mr. Scaduto has also served as the Assistant Director of Business Development at the Center for Biotechnology, as well as the founding Executive Director of the Long Island Life Sciences Initiative (LILSI). He has over 20 years of experience providing business development expertise, strategic planning services and technology commercialization guidance to emerging and expanding bioscience companies on Long Island and throughout New York State. Bring your questions! Click here to register!

Thesis Defense

Thesis Defense